SPHK1 and malignant colon neoplasm: Findings from this study suggest that oxaliplatin resistance in colon cancer cells involves the activation of SphK1/S1P/S1PR2 signaling axis that activates ERK signaling pathway resulting in the induction of CD44 expression [82].